Physician profile
Thomas J Malbrough
NPI 1609193937
$1,157.34
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $532 · 2020: $378 · 2021: $79.12 · 2023: $149 · 2024: $19.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $278.23 | 2019-2020 | |
| Nevro Corp. | $148.53 | 2023 | Senza |
| Scilex Pharmaceuticals INC. | $139.12 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $119.95 | 2019 | |
| Horizon Therapeutics Plc | $88.43 | 2019-2020 | |
| Abbott Laboratories | $69.12 | 2019-2020 | |
| Pfizer INC. | $47.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.19 | 2019 | |
| Biodelivery Sciences International, INC. | $35.83 | 2020 | |
| Virtus Pharmaceuticals LLC | $30.92 | 2021 | |
| Pacira Therapeutics, INC. | $30.66 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $24.40 | 2020 | |
| Redhill Biopharma INC. | $21.19 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $19.71 | 2024 | |
| Daiichi Sankyo INC. | $18.97 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $16.22 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.92 | 2021 | |
| Shionogi INC | $11.01 | 2019 | |
| Assertio Therapeutics, INC. | $4.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Malbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.